Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
HNSCC
MRI - Guided Adaptive RadioTHerapy for Dysphagia in Head and Neck Cancer
Recently developed hybrid machines (MRidian®-CE approval since 2016), consisting of a linear accelerator and an integrated low-field MRI, could allow better visualization of tumor and organs at risk during patient positioning and…
- Trial name
- NCT05831917
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Head and Neck Cancer
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
RATIONALE: Diagnostic procedures using the drug EF5 to detect the presence of oxygen in tumor cells may help to plan effective treatment for solid tumors.
- Trial name
- NCT00049140
- Testing
- EF5, bioluminescence, flow cytometry
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- David M. Brizel, MD
Head and Neck Cancer
Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat
RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck.
- Trial name
- NCT00012168
- Testing
- isosulfan blue, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Sponsor
- NYU Langone Health
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Head and Neck Squamous Cell Carcinoma
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT
This study compare the survival without laryngeal dysfunction 2 years after the end of treatment, obtained by chemotherapy followed by radiotherapy or chemotherapy with cisplatin administrated during radiotherapy.
- Trial name
- SALTORL (NCT03340896)
- Testing
- Docetaxel, Cisplatin, Fluorouracil
- Where
- France
- Volunteers
- 256 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Head and Neck Squamous Cell Carcinoma, Radiotherapy
Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with a 5-year survival rate of less than 50%. Radiotherapy is an important measure to control tumor recurrence.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Radiotherapy, Radiosensitizer, Pirfenidone
- Trial name
- NCT06142318
- Testing
- Pirfenidone
- Where
- 5 sites in China
- Volunteers
- 66 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Carcinoma, Squamous Cell of Head and Neck
Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy
Verify the effect and the incidence of oral mucositis of concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.
- Trial name
- NCT02753140
- Testing
- Cetuximab, radiation, Docetaxel
- Volunteers
- 60 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer
The null hypothesis is that patients screened by PET/CT will not have detection of disease recurrence any earlier than those screened by CT alone.
- Trial name
- NCT02655068
- Testing
- PET/CT, Computed Tomography (CT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pittsburgh
Squamous Cell Carcinoma, Head and Neck Cancer
Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
The purpose of the study is to determine if it is feasible to use magnetic resonance imaging (MRI) to adjust a portion of radiation therapy for patients with head and neck squamous cell carcinoma .
- Trial name
- NCT06137274
- Testing
- Intensity-modulated radiotherapy, Magnetic Resonance Guidance
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Study Objectives 1. Primary Objective: The core aim of this study is to investigate whether the sequential approach of Spatially Fractionated Radiotherapy followed by 3 cycles of induction chemotherapy combined with Iparomlimab…
- Trial name
- NCT07041788
- Testing
- Iparomlimab and Tuvonralimab Injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Head and Neck Neoplasm, Carcinoma, Squamous Cell
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood.
- Trial name
- NCT04099290
- Testing
- Blood and tumor samples
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are usually cured.
- Conditions
- Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- Best Of (NCT02984410)
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Trans Oral Surgery (TOS)
- Where
- 32 sites in Belgium, France and 6 more
- Volunteers
- 112 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
This research study is a phase Ib/II, single-arm, non-randomized, non-blind, multicenter study designed to determine whether Afatinib is effective and safe in patients with locoregionally unresectable and / or metastatic HNSCC…
- Trial name
- AFAN (NCT06648096)
- Testing
- Afatinib
- Where
- 2 sites in Germany, Spain
- Volunteers
- 25 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Head and Neck Squamous Cell Cancer
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) versus standard treatment (methotrexate, docetaxel or cetuximab) for the treatment of recurrent or metastatic head and neck squamous cell cancer (HNSCC).
- Trial name
- NCT02252042
- Testing
- Pembrolizumab, Methotrexate, Docetaxel
- Volunteers
- 495 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
In this study, patients with recurrent or metastatic head and neck squamous cell carcinoma will receive first line treatment with olaparib, pembrolizumab, and carboplatin.
- Trial name
- NCT04643379
- Testing
- Olaparib, Pembrolizumab, Carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC
At present, there are relatively clear treatment guidelines for colorectal cancer with oligometastases, while the treatment mode for resectable esophageal cancer with oligometastases is not clear and there is a lack of research…
- Trial name
- LEO (NCT05951127)
- Testing
- Esophagectomy
- Where
- 2 sites in China
- Volunteers
- 141 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tongue Cancer, Tongue Cancer TNM Staging Primary Tumor (T) T1
Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers
A prospective multicenter randomized non-inferiority clinical trial, to evaluate the efficacy and safety of 1.0 cm-safety margin surgery, compared with 1.5 cm safety margin surgery for cT1-2N0 oral tongue cancer Summary: A…
- Conditions
- Tongue Cancer, Tongue Cancer TNM Staging Primary Tumor (T) T1, Tongue Cancer TNM Staging Primary Tumor (T) T2, Surgery
- Trial name
- NCT04738786
- Testing
- 1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers, 1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- Samsung Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.